Ozempic has become one of the most talked-about drugs in the country, prescribed for both type 2 diabetes and weight loss. But behind the hype, serious risks are coming to light. Lawsuits have already tied Ozempic, Wegovy, and similar medications to gastroparesis, bowel blockages, and other severe complications. Now, a new wave of claims is emerging: an Ozempic vision lawsuit. Reports link Ozempic, Wegovy, Mounjaro, Rybelsus, and Zepbound to sudden vision loss. Patients are now filing an Ozempic blindness lawsuit after reports linked Ozempic and similar drugs to sudden vision loss.
Researchers have connected these drugs to a condition called non-arteritic anterior ischemic optic neuropathy or NAION. Some doctors even refer to it as an “eye stroke.” It happens when blood flow to the optic nerve is cut off, which can lead to sudden and sometimes permanent vision loss with little to no warning.
If you’ve noticed blurred vision, sudden loss of sight, or other serious eye problems after using Ozempic or similar medications, it may be connected. In the sections ahead, we’ll walk through what’s happening with these vision loss cases, which drugs are involved, and the options available if this has touched your life.
Ozempic (semaglutide) is a weekly injection that comes in a prefilled pen. Doctors often prescribe it to adults with type 2 diabetes to help manage blood sugar. The drug belongs to a class called GLP-1 receptor agonists, which copy the action of a natural hormone that lowers blood sugar by boosting insulin and reducing glucose release.
Novo Nordisk, a Danish pharmaceutical company, developed Ozempic in 2012. Today, it’s the only company in the U.S. with FDA-approved semaglutide products: Ozempic®, Wegovy®, and Rybelsus®. The FDA first approved Ozempic in 2017 for type 2 diabetes.
Ozempic and Wegovy are both given as weekly injections, but they serve different purposes. Ozempic is prescribed for type 2 diabetes in smaller doses (0.5 to 1 mg per week). Wegovy, on the other hand, is approved for weight loss at a higher dose (2.4 mg per week). Rybelsus is another semaglutide option, but instead of injections, it comes as a daily pill (3 mg, 7 mg, or 14 mg).
Even though Ozempic isn’t FDA-approved for weight loss, many patients using it for diabetes end up losing weight. Semaglutide works by slowing down digestion, which keeps you feeling full longer and usually leads to eating less without really trying.
Patients taking Ozempic or similar medications need to pay close attention to their eye health. While these drugs are meant to help manage blood sugar and, in some cases, aid in weight loss, they have also been linked to other serious side effects in the past, like gastroparesis, bowel blockages, nausea, and dehydration. Now, eye-related issues are emerging as another concern.
Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
NAION happens when blood flow to the optic nerve is reduced, causing permanent damage to the nerve that connects your eye to your brain. Symptoms may include:
People over 50, those with diabetes, high blood pressure, high cholesterol, sleep apnea, certain eye anatomies, or those taking medications like semaglutide (Ozempic) or sildenafil (Viagra) may have higher risks.
Eye Floaters
Floaters appear as small spots, lines, or cobweb-like shapes in your vision, often noticeable against bright backgrounds. They can be caused by:
Ozempic may contribute to floaters through changes in blood sugar, dehydration, diabetic retinopathy, or inflammatory responses.
Dry Eyes
Dry eye syndrome happens when your eyes don’t produce enough tears or tears evaporate too quickly, causing stinging, burning, blurred vision, light sensitivity, and general discomfort. While not a listed side effect, Ozempic may play a role by:
Eye Twitching
Eyelid twitching (myokymia) is usually temporary but can recur. Causes include stress, fatigue, caffeine, eye strain, nutritional deficiencies, and allergies. Ozempic may be linked to twitching through:
Other Potential Eye Issues
Patients may also notice:
Recent research has raised concerns that Ozempic, Wegovy, Mounjaro, and similar drugs may increase the risk of sudden vision problems. Doctors are particularly watching a condition called non-arteritic anterior ischemic optic neuropathy (NAION), sometimes called an “eye stroke,” which can cause permanent damage to the optic nerve.
2024 Danish/Norwegian Cohort Study
Following over 400,000 diabetes patients, researchers found that those taking semaglutide had more than double the risk of NAION compared to other diabetes medications. The absolute risk remains low, but the increase is significant for affected individuals. Early signals suggest Wegovy may carry a similar risk.
2024 Meta-analysis of Clinical Trials
Data pooled from multiple trials, including those run by Novo Nordisk, confirmed an increased risk of optic nerve injury among patients using GLP-1 drugs like Ozempic. Further research is still needed to understand the full extent.
Katz et al. Case Series (University at Buffalo)
A small series of real-world cases found that seven out of nine patients on GLP-1 drugs developed NAION or other serious vision issues, supporting the evidence seen in larger studies.
Mass Eye and Ear Study (Rutgers/Harvard)
Among diabetic patients using semaglutide, 8.9% developed NAION compared to 1.8% on other treatments. For overweight or obese patients, 6.7% developed NAION versus 0.8% on alternative therapies. These numbers highlight the severity and permanent nature of the condition.
July 2024 JAMA Ophthalmology Study
This peer-reviewed study confirmed a clear link between GLP-1 drugs and increased NAION risk, emphasizing the importance of monitoring and patient education.
December 2024 JAMA Ophthalmology Longitudinal Study
A five-year follow-up study in Denmark found that weekly semaglutide use more than doubled the risk of NAION compared to other diabetes treatments. It highlighted the need for careful monitoring, particularly for high-risk patients.
NAION is rare, but the effects can be permanent. There’s no way to reverse the damage, so it’s important to notice any vision changes early and report them to a doctor.
When reports connected Ozempic to sudden vision loss, Novo Nordisk addressed the concerns by saying the evidence isn’t strong enough to show a direct link between semaglutide and NAION. A company spokesperson noted that NAION isn’t listed as a side effect on Ozempic’s approved label and mentioned that some studies, like the one from Mass Eye and Ear, had small sample sizes and weren’t randomized. They also stressed that patient safety is a top priority and that all reports of adverse events are taken seriously.
Some people who took Ozempic or similar drugs like Wegovy and Rybelsus have suddenly experienced serious eye problems, including vision loss. Many of them are now pursuing legal action, saying that Novo Nordisk did not clearly warn about NAION, a rare condition that can lead to permanent blindness.
Losing vision can turn everyday life challenging. Things like driving, working, and even simple daily tasks can become much harder. These cases aim to hold the company responsible and help people cover medical costs, lost wages, and other challenges caused by their injuries.
The lawsuits are still moving through the courts. Some are being handled together in a multidistrict litigation to keep the process organized, while others are moving forward in state courts. For those affected, the focus is on getting fair compensation for the very real impact on their lives.
Patients experiencing vision problems or optic nerve damage have been linking their injuries to these medications:
These drugs are widely prescribed and often seen as safe but reports of sudden vision loss and other serious eye issues have raised real concerns for people taking them.
The number of lawsuits tied to Ozempic, Wegovy, and Rybelsus continues to climb. In July 2025, more patients came forward claiming the drugs caused NAION (non-arteritic anterior ischemic optic neuropathy), a condition that can lead to sudden and permanent blindness. Here are the latest developments:
August 15, 2025 – Major Ruling
Judge Karen Spencer Marston ruled that gastroparesis claims must be backed by gastric emptying studies. While this limits some cases, she allowed safety and labeling claims to move forward, keeping the core litigation alive.
August 1, 2025 – New Legal Options
A request in New Jersey seeks to consolidate NAION lawsuits into a multicounty litigation. Meanwhile, federal MDL 3072 has grown to 2,190 pending cases.
July 29, 2025 – NJ Vision Loss Cases Grow
More than 30 plaintiffs from 13 states have petitioned for a mass tort in Middlesex County over NAION claims, up from 21 in June.
July 28, 2025 – New Study
A Swedish study found Ozempic users had a 1.6 times higher risk of retinal vein occlusion, a condition that can cause sudden vision loss.
July 19, 2025 – Vision Track Requested
Plaintiffs asked the MDL court to create a separate track for over 140 cases involving blindness and other vision injuries.
July 15, 2025 – Texas Blindness Case
A woman in Texas sued Novo Nordisk after losing 90% of the vision in one eye, alleging Ozempic triggered NAION after six months of use.
June 24, 2025 – New Study Links Ozempic to Macular Degeneration
A JAMA Ophthalmology study found semaglutide users were twice as likely to develop neovascular age-related macular degeneration (nAMD), a disease that causes permanent central vision loss. While the absolute risk was small, the findings are statistically significant and biologically plausible, adding to growing concerns about GLP-1 drugs and eye health.
June 21, 2025 – New NJ Lawsuit
A man from Woodbridge, NJ, filed suit alleging Wegovy caused NAION and permanent blindness. He claims Novo Nordisk failed to warn about the risk of optic nerve damage.
June 17, 2025 – Push for Consolidation
Twenty-one New Jersey plaintiffs are seeking to combine their NAION lawsuits into a multicounty litigation. Vision loss claims are quickly becoming more prominent than the original gastroparesis lawsuits because the injuries are so severe and life-changing.
June 12, 2025 – MDL Case Count
The GLP-1 MDL (3094) in Pennsylvania now has 1,882 pending cases, mostly involving gastroparesis. More NAION cases are expected, especially once the court rules on expert evidence.
June 10, 2025 – Calls for FDA Black Box Warning
Ophthalmologists and public health advocates are urging the FDA to add a black box warning about NAION to Ozempic, Wegovy, and Rybelsus. Recent studies in JAMA Ophthalmology and Danish registries support a link to sudden vision loss. A warning would strengthen plaintiffs’ claims that Novo Nordisk knew about the risk but failed to act.
June 2, 2025 – Novo Nordisk Defense Strategy
In early filings, Novo Nordisk argued that plaintiffs’ vision loss may stem from underlying conditions like diabetes, high blood pressure, or cholesterol, not semaglutide. Plaintiffs’ attorneys counter that even a small added risk should have been disclosed, and emerging data shows NAION cases are higher than expected, even among patients with no prior eye issues.
May 19, 2025 – Vision Loss Lawsuits
New cases allege Ozempic, Wegovy, and Rybelsus caused NAION, a condition that can lead to blindness. Plaintiffs say Novo Nordisk failed to warn despite mounting evidence. Because blindness is permanent, these cases may carry higher value than the GI injury suits.
April 22, 2025 – Dismissal Arguments
Novo Nordisk and Eli Lilly asked the court to dismiss claims as vague. Plaintiffs argued their complaint is detailed, citing specific injuries and misleading marketing. The judge’s ruling will be a turning point.
April 21, 2025 – CDC Study Released
A CDC-backed study tied semaglutide to 25,000 ER visits in 2022–23, nearly half requiring hospitalization. Defendants may argue the risks are rare, but the data underscores the severity.
April 9, 2025 – Expert Challenges
Defense lawyers want gastroparesis claims thrown out unless backed by a gastric emptying study. Plaintiffs say many cases were diagnosed without the test because symptoms eased after stopping the drug.
March 26, 2025 – New Lawsuit Filed
An Illinois woman sued Novo Nordisk directly in the MDL, claiming Ozempic caused debilitating gastroparesis. She says the company knew about the risks but failed to warn.
March 17, 2025 – Eli Lilly Motion
Lilly asked the court to require “objective testing” to prove gastroparesis, aiming to block expert testimony that symptoms and clinical judgment alone can be enough. Plaintiffs argue this is an unrealistic legal hurdle meant to cut claims.
February 26, 2025 – Vision Risk Study
A JAMA Ophthalmology study of 37 million adults found semaglutide users had higher rates of NAION (14.5 cases per 100,000), a condition that can cause sudden blindness. Researchers recommend doctors warn patients of this risk.
January 28, 2025 – Thyroid Cancer Study
JAMA Otolaryngology published a study linking GLP-1 drugs like Ozempic and Mounjaro to increased thyroid cancer diagnoses within the first year. While not conclusive, it raises more safety concerns.
January 22, 2025 – Broader Risk Study
A new study showed that while GLP-1 drugs may lower risks of dementia and heart disease, they’re also linked to serious issues like GI disorders, kidney stones, arthritis, and pancreatitis. Researchers stress the need for stronger safety warnings.
December 31, 2024 – MDL Growth and Key Hearing Set
At year’s end, plaintiffs’ lawyers estimated nearly 7,000 potential cases under investigation, with projections of tens of thousands more. Judge Marston scheduled a May 20, 2025, hearing to address early discovery, preemption, label adequacy, and diagnostic standards for gastroparesis.
December 20, 2024 – Saxenda Added
The JPML expanded the MDL to include Saxenda-related claims but rejected blood clot injury cases, keeping the focus on gastrointestinal injuries like gastroparesis and intestinal blockages.
November 13, 2024 – New Case Filed
A Tennessee woman filed suit after developing confirmed gastroparesis, diagnosed with a gastric emptying study. She claims Novo Nordisk downplayed GI risks while promoting Ozempic and Wegovy as safe weight-loss solutions.
November 12, 2024 – Downplaying Risks
Plaintiffs say Novo Nordisk knew about gastroparesis risks but avoided updating labels, fearing it would scare off patients. Lawyers now see gastroparesis as the centerpiece of the litigation.
November 4, 2024 – Diagnostic Proof in Focus
Judges and lawyers are zeroing in on gastric emptying studies as the strongest evidence of gastroparesis. These tests will likely play a central role in proving claims going forward.
November 1, 2024 – Court Deadlines
Judge Marston set a schedule:
October 29, 2024 – FDA Flags Production Issues
The FDA cited Novo Nordisk’s main Denmark plant, one of only two sites making semaglutide, for failing to properly monitor water used in production. Its North Carolina facility had earlier been flagged for poor bacterial controls. Critics say Novo is rushing to meet demand and cutting safety corners.
September 16, 2024 – Vision Problems Raise Alarms
The American Academy of Ophthalmology warned that Ozempic and similar drugs may lead to blindness through conditions like diabetic retinopathy, eye strokes, or NAION. These risks are now becoming a bigger focus in the lawsuits.
July 3, 2024 – Blindness Risk Study Published
A study linked Ozempic to NAION, a rare eye stroke causing sudden blindness. Doctors reported three cases in one week. Diabetics on the drug faced four times the risk, while overweight non-diabetics faced seven. The FDA is reviewing if blindness should be added to the warning label.
June 2024 – New Judge Assigned
After Judge Gene E.K. Pratter’s passing, Hon. Karen Spencer Marston was appointed to oversee MDL 3094 (Ozempic lawsuits). At a June 10 hearing, she issued case management orders to streamline filings. This is her first multidistrict litigation case.
May 17, 2024 – Judge Pratter Passes Away
Judge Gene E.K. Pratter, who had been presiding over the Ozempic lawsuits, died at 75 from chronic obstructive pulmonary disease. She was respected for her commitment to fairness in the judicial system and had served both as a federal judge and law professor.
February 2024 – Ozempic MDL 3094 Created
On Feb. 2, 2024, the JPML consolidated all GLP-1 drug lawsuits, including Ozempic, Wegovy, Rybelsus, Trulicity, and Mounjaro, into MDL 3094 in the Eastern District of Pennsylvania, citing shared claims of gastrointestinal injuries and failure to warn. Judge Gene E.K. Pratter was assigned to oversee the cases, with thousands more expected. On Feb. 15, the Court set its first conference for March 14 to discuss leadership and scheduling. A week later, CMO #2 outlined special pro hac vice requirements for attorneys joining the MDL.
January 2024 – Early Research on Eye Risks
A systematic review linked semaglutide to blurred vision, retinopathy, and macular complications, highlighting the need for more study.
August 2021 – Retinopathy Concerns
A study found semaglutide users with existing diabetic retinopathy faced higher risks of complications, possibly tied to rapid drops in blood sugar.
June 2020 – Initial Findings
Research showed Ozempic had higher rates of diabetic retinopathy (16.4%) and ocular issues (1.1%) compared to other GLP-1 drugs.
You may qualify if:
Call Ethen Ostroff Law to see if you qualify.
Act quickly if you’ve been taking Ozempic, Wegovy, Rybelsus, Mounjaro, or Zepbound and notice vision changes. Early attention can help protect your eyesight and keep your options open if you need to take legal steps.
See a Doctor Right Away
If your vision becomes blurry, you have trouble focusing, or you suddenly lose sight, contact your healthcare provider as soon as possible. They can check for problems like optic nerve damage or diabetic eye complications and figure out if your medication might be involved.
Get a Thorough Eye Exam
Your doctor may refer you to an eye specialist. Regular exams are important if you’re on medications that could affect your eyes, or if your symptoms are getting worse. Eye specialists can track changes and recommend needed treatment.
Keep Track of Everything
Write down any changes in your vision, when they happen, and how bad they are. Save your test results and notes from appointments. This record can help your doctors and may be important if you decide to pursue an Ozempic blindness lawsuit.
Talk to an Ozempic Lawyer
If you think your vision problems are linked to Ozempic or other semaglutide drugs, talking to a lawyer who handles these cases can help. Lawyers at Ethen Ostroff Law can review your situation, explain your options, and assess if you qualify for an Ozempic vision loss lawsuit.
If you’ve noticed vision problems after taking Ozempic, Wegovy, Rybelsus, Mounjaro, or Zepbound, here’s a practical approach:
Talk to a lawyer experienced in Ozempic vision loss lawsuits
Start with a consultation. A qualified attorney can confirm if you qualify and explain any deadlines for filing a personal injury claim.
Gather your records
Collect medical reports, prescriptions, doctor’s notes, test results, and bills. Anything showing you took a semaglutide drug and experienced NAION or other vision problems helps support your Ozempic blindness lawsuit.
Stay involved with your lawyer
Keep your attorney updated and provide any details they need. This helps them prepare a clear, strong Ozempic lawsuit for you.
Consider settlement or trial options
Your lawyer will guide you if it’s better to negotiate a settlement or take your lawsuit against Ozempic to trial. Some cases resolve faster through negotiation, while others proceed to court.
Compensation
If your case succeeds, you may recover funds for medical expenses, lost wages, and other damages caused by vision loss.
Careful documentation is key. Clear records show the full impact of your health issues and help your lawyer make the strongest Ozempic vision loss lawsuit.
Gather any records that show how Ozempic or similar drug affected your vision to give your lawyer a clear picture of what happened:
Have these ready to help your lawyer understand your case and support your claim.
If your Ozempic blindness lawsuit is successful, you could be eligible for compensation that covers the real impact this has had on your life, including:
This compensation is meant to help cover the financial and personal toll caused by vision damage from these medications.
You have a limited time to file a claim. The window in most states is usually two to three years from when you first noticed vision problems or realized they could be linked to the medication. In Pennsylvania, the typical deadline is three years. Consult with a lawyer at Ethen Ostroff Law as soon as possible to avoid missing your opportunity to pursue a claim.
If you’ve experienced vision problems from Ozempic or other semaglutide drugs, reach out to an Ozempic lawyer at Ethen Ostroff Law as soon as possible. Filing a claim has time limits—most states only allow 2-3 years from when your vision issues started or when you discovered a link to the medication. Acting quickly helps make sure you don’t miss your chance to seek compensation.
We handle cases involving the Ozempic class action lawsuit, Mounjaro blindness, Ozempic Wegovy blindness, and Ozempic blurry vision. We’ll guide you through the process, help gather the necessary medical records and explain your options, so you have the best chance to recover damages for medical bills, lost income, and other effects of vision loss.
Call us now for a free case review.
Yes, it can. Some people experience blurred vision, and in rare cases, it has been linked to a condition called non-arteritic anterior ischemic optic neuropathy (NAION), which damages the optic nerve. If you already deal with diabetes-related eye issues, Ozempic may make them worse, so regular eye checkups are a good idea.
Yes, but it’s uncommon. Studies suggest Ozempic can raise the risk of a condition that cuts off blood flow to the optic nerve, which can cause permanent vision loss. Most people won’t run into this, but sudden changes in vision should always be taken seriously.
Yes, there have been cases reported. Vision loss usually happens because of optic nerve damage. Unfortunately, it can be permanent in one eye. Some people have already filed lawsuits over this, saying they weren’t warned about the risk.
You might qualify, if you took Ozempic (or similar drugs like Wegovy or Rybelsus) and later developed serious health problems. This includes things like stomach paralysis, bowel blockages, gallbladder issues, or vision loss. Our lawyer can go over your medical history and let you know if you have a case.
That depends on your situation. People with severe injuries like permanent vision loss or serious stomach problems have seen cases in the hundreds of thousands, sometimes higher. The amount usually comes down to medical costs, lost wages, and how much the condition has affected daily life.
His career began in public service as a Surveillance Officer in Maricopa County, where he gained firsthand experience in high-stakes decision-making and developed a deep sense of discipline and accountability. He later served as Chief Operating Officer of a fast-growing law firm, driving efficiency, revenue growth, and team development. Today, Ryan focuses on helping law firms reach their full potential by aligning people, processes, and long-term vision. A strategic thinker and empowering leader, Ryan is passionate about developing others and guiding organizations through meaningful, lasting growth.
Effective Date: 10/15/2026
Ethen Ostroff Law, PLLC (“EOL,” “we,” “us,” or “our”) respects your privacy. If you are reaching out to us after an injury, we know you may be sharing personal details during a hard time. This Privacy Policy explains what information we collect when you visit ethenostrofflaw.com (the “Site”), how we use it, who we share it with, and the choices you have.
This Privacy Policy works together with our Terms of Use. By using the Site, you agree to the practices described here. If you do not agree, please do not use the Site.
Visiting the Site, submitting a form, chatting with us online, or sending us an email does not create an attorney-client relationship. An attorney-client relationship begins only when you and EOL sign a written Retainer Agreement. Until then, information you send us is not protected by attorney-client privilege and is not considered confidential. Please do not send sensitive details about your matter until we have spoken with you.
When you request a free consultation, fill out a form, use our live chat, call, text, or email us, you may give us:
When you visit the Site, we and the third-party tools described in section 8 may automatically collect:
We may share your information with:
If you opt in to text messages, you may receive messages about your inquiry or case. Message frequency varies, and message and data rates may apply. Reply STOP at any time to opt out, or HELP for help. Mobile phone numbers and text message opt-in consent will not be shared with third parties or affiliates for their own marketing purposes.
We do not send the details you type into our intake forms, contact forms, or live chat, such as information about your injury or legal matter, to Google, Meta, TikTok, Reddit, or any other advertising platform.
The Site uses cookies, pixels, and similar tools. A cookie is a small file stored in your browser. A pixel is a small piece of code that loads when you visit a page and sends information about your visit to the company that provides it. We use Google Tag Manager to load and manage these tools.
The table below lists the third-party tools on the Site and what we use them for.
| Provider | What we use it for | Provider privacy policy |
| Google Tag Manager | Loads and manages the other tools listed here. It does not build a profile of you. | policies.google.com/privacy |
| Google Analytics | Understanding how visitors use the Site, such as pages viewed and how they found us. | policies.google.com/privacy |
| Google Ads | Measuring ad conversions and showing our ads to past visitors. | policies.google.com/privacy |
| Meta Pixel (Facebook and Instagram) | Measuring ad performance, showing our ads to past visitors, and reaching similar audiences. | facebook.com/privacy/policy |
| TikTok Pixel | Measuring ad performance, showing our ads to past visitors, and reaching similar audiences. | tiktok.com/legal/privacy-policy |
| Reddit Pixel | Measuring ad performance, showing our ads to past visitors, and reaching similar audiences. | reddit.com/policies/privacy-policy |
| Intaker | Powers the live chat on the Site so you can reach our intake team. | intaker.com |
| OpenWidget (ChatBot.com) | Powers the chat assistant on the Site. | openwidget.com |
| Google reCAPTCHA | Protects our forms from spam and automated abuse. | policies.google.com/privacy |
| Google Maps | Displays maps of our office locations. | policies.google.com/privacy |
These tools may collect the information listed in section 3. If you give us your email address or phone number, a scrambled (hashed) version may be sent to an advertising platform so it can match your visit to an existing account.
Google, Meta, TikTok, and Reddit may combine the information they receive with other data they hold about you and use it under their own privacy policies. You can learn how Google uses information from sites that use its services at policies.google.com/technologies/partner-sites.
Some state privacy laws, including California’s, may treat sharing information through advertising pixels as a “sale” or “sharing” of personal information, or as targeted advertising. Depending on where you live, you may have the right to know what information we hold about you, to ask us to correct or delete it, and to opt out of its sale or sharing. To make a request, contact us using the information in section 15. We may need to verify your identity before we respond. We will not treat you differently for using these rights.
We use reasonable administrative, technical, and physical safeguards to protect your information. No method of sending or storing data over the internet is completely secure, so we cannot guarantee the security of information you send us.
We keep your information as long as we need it for the purposes described in this policy, including to meet legal, ethical, and record-keeping obligations.
The Site is not directed to children under 13, and we do not knowingly collect personal information from them online. If a parent or guardian is contacting us about a child’s injury, the parent or guardian should submit the inquiry.
We may update this policy when we add, change, or remove tools on the Site or change how we handle information. We will post the updated version here and change the effective date above.
If you have questions about this policy or want to make a privacy request, contact us:
